Stay updated on market trends for XLO. Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? AbbVie and Xilio partner to develop tumor-activated immunotherapies.

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. (ABBV). The two companies announced a collaboration and option-to ...

Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced pipeline and business highlights and reported financial results for the ...

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) increased during the last reporting period, rising from 575.45K to 644.54K. This put 1.46% of the company's publicly available shares short.